Drugs / TissueGene-C
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02341391 | Feb 2007 → Aug 2008 | osteoarthritis | Kolon Life Science | Completed | No outcome recorded |
| Phase 1 | NCT00599248 | Jan 2007 → May 2009 | osteoarthritis, knee | Kolon TissueGene, Inc. | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT01825811 | Oct 2012 → Apr 2014 | osteoarthritis | Kolon Life Science | Completed | No outcome recorded |
| Phase 2 | NCT01671072 | Jul 2011 → Oct 2012 | osteoarthritis | Kolon Life Science | Completed | No outcome recorded |
| Phase 2 | NCT01221441 | May 2011 → Oct 2013 | osteoarthritis, knee | Kolon TissueGene, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02341378 | Aug 2009 → Jun 2010 | osteoarthritis, knee | Kolon Life Science | Completed | No outcome recorded |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT02072070 | Nov 2013 → Aug 2015 | osteoarthritis | Kolon Life Science | Completed | Met primary |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TissueGene-C | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00599248 ↗ |
| Known as | TG-C | “The aim of this study was to test the clinical efficacy of TissueGene-C (TG-C), a cell and gene therapeutic for osteoarthritis consisting of non-transformed and transduced...” PMID 29641281 ↗ Mar 2018 |
| Action | Restore | “safely regenerate cartilage without invasive surgery” NCT01221441 ↗ |
| Modality | Cell therapy | “cell-mediated gene therapy” NCT00599248 ↗ |
| Route | Other | “intra-articular injection” NCT00599248 ↗ |
| Target | TGFB1 | “retrovirally transduced to overexpress transforming growth factor-β1” PMID 29641281 ↗ Mar 2018 |